Cover Image
市場調查報告書

末梢神經病變(感覺神經病變):開發平台分析

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192768
出版日期 內容資訊 英文 86 Pages
訂單完成後即時交付
價格
Back to Top
末梢神經病變(感覺神經病變):開發平台分析 Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 86 Pages
簡介

所謂末梢神經病變,是指從末梢神經系統──腦、脊髓(中樞神經系統)傳達到人體各處資訊的廣大通訊網──的損壞。主要的症狀為,火燒般或電到般的疼痛,皮膚、頭髮、指甲的變化,協調功能障礙,肌肉無力,麻痺狀態(運動神經發病時)等。易罹病素質,有糖尿病和酒精濫用、感染疾病(萊姆病、帶狀皰疹(水痘帶狀皰疹)、EB病毒、C型肝炎、HIV病毒等)、對腎臟、肝臟、甲狀腺疾病、毒素的暴露等。主要的治療藥,有抗憂鬱劑和免疫抑制劑,抗癲癇藥等。

本報告提供全球各國的末梢神經病變(感覺神經病變)治療用的開發中產品的開發情形相關分析、產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽、主要企業簡介、主要藥物概要、最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

末梢神經病變(感覺神經病變)概要

治療藥的開發

  • 末梢神經病變開發中產品:概要
  • 末梢神經病變開發中產品:比較分析

各企業開發中末梢神經病變治療藥

大學/研究機關研究中的末梢神經病變治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

末梢神經病變治療藥:開發中的產品一覽(各企業)

末梢神經病變治療藥:研究中的產品一覽(各大學/研究機關)

開發末梢神經病變治療藥的企業

  • Arcturus Therapeutics, Inc
  • aTyr Pharma, Inc.
  • GeNeuro SA
  • INSYS Therapeutics, Inc.
  • 田邊三菱製藥
  • Neuren Pharmaceuticals Limited
  • Pfizer Inc.
  • Polyneuron Pharmaceuticals AG
  • RegeneRx Biopharmaceuticals, Inc.
  • TEIJIN FIBERS製藥

末梢神經病變:治療藥的評估

  • 單劑治療藥的情況
  • 各標靶
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • (immune globulin (human) + hyaluronidase (recombinant))
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • Cannabidiol
  • fingolimod hydrochloride
  • GL-2045
  • immune globulin (human)
  • immune globulin (human)
  • LUNAR-102
  • Monoclonal Antibody for CIDP
  • NNZ-2591
  • Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma
  • Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma
  • PN-1007
  • Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder
  • RGN-352
  • Synthetic Peptides for Peripheral Neuropathy

末梢神經病變治療藥:開發中產品的最新趨勢

末梢神經病變治療藥:開發暫停的產品

末梢神經病變治療藥:開發中止的產品

末梢神經病變相關產品的開發的里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8291IDB

Summary

Global Markets Direct's, 'Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2016', provides an overview of the Peripheral Neuropathy (Sensory Neuropathy) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Peripheral Neuropathy (Sensory Neuropathy)
  • The report reviews pipeline therapeutics for Peripheral Neuropathy (Sensory Neuropathy) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Peripheral Neuropathy (Sensory Neuropathy) therapeutics and enlists all their major and minor projects
  • The report assesses Peripheral Neuropathy (Sensory Neuropathy) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Peripheral Neuropathy (Sensory Neuropathy)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Peripheral Neuropathy (Sensory Neuropathy) Overview
  • Therapeutics Development
    • Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Overview
    • Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis
  • Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Development by Companies
  • Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Investigation by Universities/Institutes
  • Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Peripheral Neuropathy (Sensory Neuropathy) - Products under Development by Companies
  • Peripheral Neuropathy (Sensory Neuropathy) - Products under Investigation by Universities/Institutes
  • Peripheral Neuropathy (Sensory Neuropathy) - Companies Involved in Therapeutics Development
    • Araim Pharmaceuticals, Inc.
    • CSL Limited
    • GeNeuro SA
    • Mitsubishi Tanabe Pharma Corporation
    • Neuren Pharmaceuticals Limited
    • Pfizer Inc.
    • Pharnext SAS
    • Polyneuron Pharmaceuticals AG
    • RegeneRx Biopharmaceuticals, Inc.
    • Sanofi
    • Shire Plc
    • Teijin Pharma Limited
  • Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (baclofen + naltrexone + sorbitol) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (hyaluronidase (human) (recombinant) + immune globulin (human)) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aminoquinol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cibinetide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDE-1204 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fingolimod hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GL-2045 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GNbAC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NNZ-2591 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PN-1007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RGN-352 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-184841 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Peripheral Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects
  • Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products
  • Peripheral Neuropathy (Sensory Neuropathy) - Product Development Milestones
    • Featured News & Press Releases
      • Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder
      • Jul 12, 2013: Neuren Receives Notice of Allowance for New Patent
      • Apr 04, 2013: CSL Behring's Privigen Obtains European Approval For Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy
      • Feb 21, 2013: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For CSL Behring's Privigen
      • Jun 27, 2012: PRIMA Study Shows Treatment With Privigen Improved Function In Patients With Chronic Inflammatory Demyelinating Polyneuropathy
      • May 30, 2012: CSL Behring Submits Marketing Authorization Variation Application To EMA For Privigen In Chronic Inflammatory Demyelinating Polyradiculoneuropathy
      • Mar 26, 2012: CSL Behring Enrolls First Patient In PATH Trial To Evaluate Hizentra For Treatment Of CIDP
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H2 2016
  • Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Araim Pharmaceuticals, Inc., H2 2016
  • Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by CSL Limited, H2 2016
  • Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by GeNeuro SA, H2 2016
  • Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
  • Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Neuren Pharmaceuticals Limited, H2 2016
  • Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Pfizer Inc., H2 2016
  • Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Pharnext SAS, H2 2016
  • Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Polyneuron Pharmaceuticals AG, H2 2016
  • Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016
  • Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Sanofi, H2 2016
  • Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Shire Plc, H2 2016
  • Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Teijin Pharma Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects, H2 2016
  • Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects (Contd..1), H2 2016
  • Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H2 2016
  • Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top